Reneuron Share Discussion Threads

[masingi] 01/11/2017 14:19

ps0u3165: "I can see the wood, however most of the trees have been burn't. Look at the LT chart and tell me which way its trending. IMHO it will not change significantly for a long time to come."

...unless there is a buy-out, a marketing deal, a US stock listing, or the market starts to price-in future potential as results come through.

All of which is driven by rumour and news. Rumour and news cannot be predicted by LT trends. Not much can, to be honest. All I can suggest is buy into the falls and sell into the rises (not the other way round).

[ps0u3165] 01/11/2017 14:08

I can see the wood, however most of the trees have been burn't. Look at the LT chart and tell me which way its trending. IMHO it will not change significantly for a long time to come.

[audigger] 01/11/2017 12:54

I added another chunk yesterday. Clinical development programs take years so we have some way to go. Trial design will be influenced by statistical robustness not cost. If they need more money, the impact will be minimal compared to the potential upside. My main concerns about the ability of that potential to be realised are:
1) will the treatment work? All the indications to date are that it does
2) is it cost effective such that agencies will approve it for use....NHS won't pay if it's too expensive!
3) is there any competition that can beat them to market. I don't know for sure but my understanding is that they are the front runners

If further trials reinforce the effectiveness they there's a high chance that regulatory approvals will be expedited. I've no clue as to the potential upside in share price but it has to be many multiples of where we are today. For me, the risks are worth the potential upside and the risk is that they fail to deliver an effective product and I loose all of my investment.

[small crow] 01/11/2017 12:00

I somehow suspect he doesn't want to see the wood....

[bigspuds] 01/11/2017 11:11

Only one more study before market. Says it quite clearly, you just need to see the wood for the trees

[small crow] 01/11/2017 11:02

I predict a TO before any more cash calls. There's boldness for you.

[ps0u3165] 01/11/2017 10:39

Patience been waiting over 10 yrs to-date. Last cash call was at 3p, next 1p?

Edit

[bonzo] 01/11/2017 09:54

Of course they will need funds; with a world changing treatment for stroke these should be easy to come by.

[small crow] 01/11/2017 09:53

Patience always needed!

[ps0u3165] 01/11/2017 09:50

So we could be talking years not months. If so the cash will be gone, they may have cut the sample size to keep the cash burn down. However its unlikely to see any product through to market so more cash calls will be needed.

[small crow] 01/11/2017 09:37

As a takeover target this seems amazingly tempting. Cash in the bank and loads of potential. I know big pharma doesn't take risks but, given the cash situation, the potential is pretty well free.

[small crow] 01/11/2017 07:51

All depends on dialogue with the regulators!

[ps0u3165] 01/11/2017 07:44

small crow

So how long do you estimate a time frame for a pivotal study. On top of the randomised, placebo-controlled clinical trial, data due H2 2019.

[small crow] 01/11/2017 07:13

ps0

Not discouraging at all - of course it needs a proper, randomised trial. However, there are many ways of doing this and design discussions with, for example, the FDA may reduce the constraints and speed up the process if they see potential benefits.

[kwizza] 31/10/2017 22:43

ReNeuron's Michael Hunt discusses very encouraging long-term stroke data

www.proactiveinvestors.co.uk/companies/stocktube/8308/reneuron-s-michael-hunt-discusses-very-encouraging-long-term-stroke-data-8308.html

[bonzo] 31/10/2017 11:57

For reasons unknown the market hates this company and punishes at every turn. Incomprehensible.

[ps0u3165] 31/10/2017 09:48

You missed this bit. Is this discouraging news for share holders?

The Company will continue its discussions with regulatory authorities worldwide but anticipates that a further pivotal study will likely be required for global marketing approval of the therapy.

[rob the slob] 31/10/2017 09:35

"The Company will, as planned, shortly submit an Investigational New Drug application to the FDA to commence a randomised, placebo-controlled clinical trial in the US in disabled stroke patients. This study will involve fewer patients than the study originally planned with data expected to be available earlier, in the second half of 2019.""fewer patients" reads to me that the response rate seen means statistically fewer patients are needed. For "fewer patients" read less research costs! This is very encouraging news for shareholders.

[stewart_25] 31/10/2017 08:37

Great news - and how will the share price respond? 2-3 years ago this would have spiked by 200-300% on news like this.

[small crow] 31/10/2017 07:28

Good news. Particularly encouraging is this: " The primary efficacy measure of the PISCES II study, motor function using the Action Research Arm Test (ARAT), improved between three and 12 months post-treatment. " So perhaps improvements continue years after treatment, which could be life-changing for these people. Also wonder whether the next proper (with control) trial is using exactly the same CTX treatment or any improved methodology - anyone know?

[stewart_25] 30/10/2017 14:47

very positive presentation - just need the share price to start moving

[deutsch3] 24/10/2017 10:21

We need to inject some stem cells into the Management to get the share price moving.
It appears as if they are helping 'someone?' get a bundle out!

[stewart_25] 24/10/2017 10:10

nice article i found yesterday about stem cells being injected into back discs to alleviate pain and improve movement - not rene but related...